NCT05823740Completed
Measuring Changes in Body Composition and Physical Function in Patients With Childhood Cancers
Source: ClinicalTrials.gov · Last updated 1 May 2026
Brief summary (registry, in English)
The primary objective of this study is to evaluate the feasibility and acceptability of obtaining repeated measurements of lean muscle mass, physical function, and biological aging in children receiving active cancer therapy. The secondary objective is to evaluate the feasibility of using the D3-creatine dilution method (D3Cr) to measure skeletal muscle mass in children with cancer. Assessments will be collected at diagnosis, once during active treatment, and end of treatment in coordination with routine imaging to monitor changes in study outcomes during active cancer treatment. Key sociodemographic, treatment and health-related factors will be abstracted from the medical record.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 28 (actual)
- First submitted
- 10 Apr 2023
- Start date
- 1 May 2023
- Primary completion date
- 21 Feb 2026
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Diseases
- Childhood cancers
- NCT number
- NCT05823740
What you commit to
- Study type: Interventional
- Participants enrolled: 28
- From 1 May 2023 to the primary completion date, 21 Feb 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Treatment with surgical excision alone
- Subject has elected to forgo chemotherapy or radiotherapy.
Other illness
- Prior history of cancer
Other
- Planned palliative treatment.
- Any diagnosis of leukemia.
- Clinical concerns that the treating clinician feels would preclude participation in the study.
- Subject has a pacemaker or bilateral joint prosthesis that would prevent undergoing BIA assessment.
- Unwilling to sign informed consent.
- Speak a language other than English or Spanish.
Who the study is looking for
- Ages 8-21 years at the time of cancer diagnosis
- Must have a newly diagnosed malignant solid tumor or lymphoma.
- Participant is expected to undergo cancer treatment with either chemotherapy, radiation, immunotherapy, or other biologically targeted therapy.
- Participants will undergo routine imaging with either computed tomography (CT), or Magnetic Resonance Imaging (MRI) of the chest or abdomen, or whole-body positron emission tomography (PET) scan.
- Written informed consent obtained to participate in the study and HIPAA authorization for the release of personal health information.
- English or Spanish speaking
- Subject is willing and able to comply with study procedures.
- Since the patient is undergoing active cancer therapy, must obtain approval from the treating physician.
Age in the registry: 8 years to 21 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| UNC Lineberger Comprehensive Cancer Center Coordinator of this site? Confirm its status | Chapel Hill | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.